In the Journals

Study challenges ‘default use of hypomethylating agents’ in high-risk myelodysplastic syndrome

November 15, 2019
Older patients with myelodysplastic syndrome appeared more likely to receive persistent treatment with hypomethylating agents under the care of more…

In the Journals

Oral blood cancer drug may worsen cardiometabolic health

November 13, 2019
An oral chemotherapy treatment used to treat myeloproliferative neoplasms is associated with substantial weight gain and increased systolic blood…

In the JournalsPerspective

Symptom burden a key component of disease control assessment in polycythemia vera

November 8, 2019
Patients with polycythemia vera can experience high symptom burden even if their blood counts are controlled, according to an analysis from the…

FDA News

FDA restructures, renames office that reviews cancer therapies

November 6, 2019
The FDA office that reviews applications for cancer therapies has been renamed and reorganized. The Center for Drug Evaluation and Research’s…

ASH elects three to leadership positions

October 31, 2019
ASH announced the election of three clinicians to leadership positions within the society. Jane Winter, MD, will serve a 1-year term as vice…

ASH presents bridge grants to 19 investigators

October 7, 2019
ASH awarded $150,000 each to 19 investigators through the society’s bridge grant program, designed to sustain promising hematologic research…

Meeting News

IASLC: All physicians should screen patients with cancer for tobacco use

September 7, 2019
BARCELONA — The International Association for the Study of Lung Cancer, or IASLC, today issued a declaration at its World Conference on Lung…

In the Journals

Familial risks identified across hematologic malignancies

August 30, 2019
Individuals with a child, parent or sibling with a hematologic malignancy may be at higher risk for being diagnosed with the same disease, according…

FDA News

FDA approves Inrebic for myelofibrosis

August 16, 2019
The FDA today approved fedratinib for the treatment of adults with intermediate-2 or high-risk primary or secondary myelofibrosis…

FDA News

FDA issues class 1 recall of filter tips for assays

August 2, 2019
The FDA has issued a class 1 recall — the most serious kind of recall — of Qiagen’s pipetting system filter tips. The recall…

Meeting News

ASH announces award recipients

July 15, 2019
Several distinguished leaders in hematology will be honored with awards and special lectures at this year’s ASH Annual Meeting and Exposition…

St. Jude Children’s Research Hospital physician-scientist receives award

July 12, 2019
Esther Obeng, MD, PhD, received the 2019 Gertrude B. Elion Cancer Research Award from American Association for Cancer Research. The award supports…

In the JournalsPerspective

Next-generation hypomethylating agent shows promise for intermediate-, high-risk myelodysplastic syndrome

July 11, 2019
Guadecitabine demonstrated clinical activity with acceptable toxicity among patients with intermediate- and high-risk myelodysplastic syndrome…

Feature

Dana-Farber clinic to focus on blood cancer precursor conditions

June 28, 2019
Dana-Farber Cancer Institute opened a new clinic designed to improve clinical care and monitoring for individuals with precursor conditions that can…

FDA News

FDA grants fast track designation to momelotinib for myelofibrosis

June 5, 2019
The FDA granted fast track designation to momelotinib for the treatment of patients with intermediate- or high-risk myelofibrosis who previously…

Meeting News

Atul Gawande, MD, MPH: When treating patients, ‘our core goal is to enable their goals’

June 1, 2019
CHICAGO — When treating

Feature

AI has potential to disrupt and transform cancer care, center director says

May 24, 2019
Translating genomic and big data into clinical tools for physicians and patients with cancer is an enormous challenge that has been enthusiastically…

In the JournalsPerspective

Previous hematologic malignancies increase risk for head and neck cancers

May 23, 2019
Individuals previously diagnosed with a hematologic malignancy appeared at higher risk for developing head and neck cancers, according to results of…

In the Journals

High-dose irradiation before HSCT increases risk for subsequent malignancies

May 21, 2019
Survivors of allogeneic hematopoietic cell transplantation who underwent high-dose total body irradiation incurred nearly eight times the risk for…

In the Journals

Precision medicine ‘can now be a reality’ for hard-to-treat pediatric cancers

May 20, 2019
Comprehensive molecular profiling feasibly identified potentially actionable mutations among children and adolescents with hard-to-treat cancers…